Emerging research suggests these drugs may reduce inflammation through multiple mechanisms, potentially contributing to their cardiovascular and renal benefits
GLP-1s are not recommended during pregnancy or while trying to conceive, as theres not enough safety data
They activate GLP-1 receptors in the gastric fundus and antrum, reducing gastric motility and pyloric relaxation
In 1990, a Canadian endocrinologist first isolated Exendin-4 from a Gila monsters saliva
Eli Lilly is also developing a drug called retatrutide, that targets three receptors (glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors)
Flint A, Raben A, Blundell JE, Astrup A